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SUMMARY
The steady-state airway epithelium has a low rate
of stem cell turnover but can nevertheless mount
a rapid proliferative response following injury. This
suggests a mechanism to restrain proliferation at
steady state. One such mechanism has been identi-
fied in skeletal muscle in which pro-proliferative
FGFR1 signaling is antagonized by SPRY1 to main-
tain satellite cell quiescence. Surprisingly, we found
that deletion of Fgfr1 or Spry2 in basal cells of the
adult mouse trachea caused an increase in steady-
state proliferation. We show that in airway basal
cells, SPRY2 is post-translationally modified in
response to FGFR1 signaling. This allows SPRY2 to
inhibit intracellular signaling downstream of other
receptor tyrosine kinases and restrain basal cell pro-
liferation. An FGFR1-SPRY2 signaling axis has previ-
ously been characterized in cell lines in vitro. We
now demonstrate an in vivo biological function of
this interaction and thus identify an active signaling
mechanism that maintains quiescence in the airway
epithelium.
INTRODUCTION
The airway epithelium of both mouse and humans is essentially
quiescent at steady state, with an extremely low rate of stem
cell proliferation (Cole et al., 2010; Kauffman, 1980; Teixeira
et al., 2013). Nevertheless, airway basal cells (BCs) can rapidly
enter the cell cycle in response to luminal cell loss (Hong et al.,
2004; Pardo-Saganta et al., 2015; Rawlins et al., 2007). Several
paracrine signaling pathways that promote airway stem cell
proliferation following injury have been characterized (reviewed
in Hogan et al., 2014). In addition, autocrine signaling mecha-
nisms can initiate airway proliferation in response to local
damage (Vermeer et al., 2003). A critical question remains:
are there are also mechanisms which actively inhibit airway
proliferation at homeostasis and therefore function to maintain
quiescence?
In overall organization the mouse trachea is very similar to hu-
man smaller airways (Hackett et al., 2011; Rock et al., 2010; Teix-
eira et al., 2013). The adult mouse tracheal epithelium comprises
threemain cell types. BCs include both slowly dividing stem cells
and committed luminal precursors (Mori et al., 2015; Rock et al.,
2009; Watson et al., 2015). Luminal secretory cells can self-
renew and produce luminal ciliated cells, while ciliated cells are
terminally differentiated (Rawlins and Hogan, 2008; Rawlins
et al., 2007, 2009). In vitro and in vivo evidence suggests that
airway BC proliferation requires epidermal growth factor recep-
tor (EGFR) activity (Brechbuhl et al., 2014; You et al., 2002).
Moreover, inhibition of EGFR signaling via contact inhibition is
necessary to restrain BC proliferation following injury (Lu et al.,
2013). WNT and Notch signaling can also promote BC prolifera-
tion in some contexts (Giangreco et al., 2012; Paul et al., 2014;
Rock et al., 2011). By contrast, YAP prevents differentiation of
BCs (Mahoney et al., 2014; Zhao et al., 2014). However, no spe-
cific signaling pathways that actively inhibit BC proliferation at
steady state have been identified.
In other organs, stem cell quiescence is actively maintained by
feedback inhibition. For example, in the satellite cells of skeletal
muscle steady-state quiescence requires the function of specific
receptor tyrosine kinase (RTK) inhibitors, SPRY proteins, to
antagonize pro-proliferative fibroblast growth factor receptor 1
(FGFR1) signaling (Chakkalakal et al., 2012; Shea et al., 2010).
We speculated that similar mechanisms would operate in the
steady-state airway epithelium.
FGFR signaling has been extensively studied in lung develop-
ment and the smaller conducting airways (e.g., Abler et al., 2009;
Volckaert et al., 2011, 2013; Yin et al., 2011) where, similar to its
role in muscle, it has been found to have a pro-proliferative func-
tion. However, the role of FGFR signaling in airway BCs remains
undetermined. We therefore tested whether antagonism of
FGFR1 activity by SPRY proteins is required for BC quiescence.
Surprisingly, we found that deletion of either Fgfr1 or Spry2 re-
sulted in increased levels of BC proliferation. We demonstrate
that in airway BCs, SPRY2 is post-translationally modified down-
stream of FGFR1, allowing SPRY2 to antagonize signaling from
other RTKs, most likely EGFR, and maintain quiescence. There
is a well-documented in vitro relationship between FGFR1-medi-
ated modification of SPRY2 and RAS-ERK inhibition (Lao et al.,
2006, 2007). However, a role for this interaction has never previ-
ously been identified in vivo.
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RESULTS
FGFR1 Signaling Is Required for Normal Tracheal
Cellular Homeostasis
FGFR signaling pathway components are readily detected in the
steady-state adult mouse trachea by RT-PCR (Figure S1A). Fgfr1
and Spry2 mRNA were also detected in purified BC, secre-
tory, and ciliated cell populations by qRT-PCR (Figures 1A,
S1B, and S1C) and by single-cell qRT-PCR (Watson et al.,
2015). Moreover, FGFR1 protein and mRNA were detected in
BCs and luminal cells in the intact mouse trachea (Figures S1D
and S1F). We conditionally deleted Fgfr1 and activated a GFP
reporter in tracheal BCs using Tg(KRT5-CreER); Rosa26R-
fGFP; Fgfr1D/fx (Fgfr1 conditional knockout, cKO) and control
Figure 1. Deletion of Fgfr1 in BCs Results in
Altered Tracheal Epithelial Homeostasis
(A) Relative expression of Fgfr1 and Spry2 mRNA in
sorted wild-type basal, secretory, and ciliated cells.
(B) Schematic of Fgfr1 conditional knockout exper-
iment.
(C) Relative expression of Fgfr1 mRNA in sorted
GFP+ BCs from control and Fgfr1 cKOmice 3weeks
after tmx administration.
(D) Representative confocal sections from control
Tg(KRT5-CreER);Rosa26RfGFP/+ and cKO Tg(KRT5-
CreER); Rosa26RfGFP/+; Fgfr1D/fx tracheae. Green,
GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei).
Increased labeling of luminal cells is visible in the
Fgfr1 cKOs by 5 weeks (arrowheads), becoming
large patches of labeled cells (brackets) by 13 and
24 weeks.
(E) Percentage of the total T1a+ BCs that are also
GFP+.
(F) Percentage of total T1a luminal cells that are
also GFP+.
Error bars denote SEM. Scale bars, 50 mm. See also
Figures S1 and S2.
Tg(KRT5-CreER); Rosa26R-fGFP mice.
Four doses of tamoxifen (tmx) were admin-
istered to adult (>8 weeks old) mice (Fig-
ure 1B). To confirm deletion of Fgfr1fx in
the GFP+ BCs, we performed qRT-PCR
on pools of isolatedGFP+BCs and showed
that the level of Fgfr1 mRNA in the Fgfr1
cKOs was reduced to 20% of the control
level (Figure 1C). This result showed
that widespread co-recombination of the
Fgfr1fx and Rosa26RfGFP loci was occur-
ring, and we used GFP+ cells as a surro-
gate marker for Fgfr1D/D cells in further
experiments. However, it is important to
note thatRosa and Fgfr1 co-recombination
is 80%, and we therefore underestimate
the extent of the Fgfr1 phenotype using
this scoring method.
Tracheae were harvested at intervals
and processed for histology to assess
the contribution of GFP+, Fgfr1D/D BCs to
the epithelium during normal homeostatic
turnover. At 1.5 weeks after tmx administration, 30% of total
BCs were GFP+ in both Fgfr1 cKOs and controls. In control
animals this percentage increased modestly to 40%–50% at
5–13 weeks after tmx administration, before dropping to initial
levels by 24 weeks. This change was much more marked in
the Fgfr1 cKO mice, in which the percentage of labeled BCs
peaked at 60% at 13 weeks before returning to initial levels (Fig-
ures 1D and 1E). In both genotypes, labeled BCs produced
labeled luminal cells as expected. However, luminal cell produc-
tion was greater in the Fgfr1 cKO mice, with levels of GFP+
luminal cells reaching 38% ± 2% of the total luminal cell popula-
tion by 24 weeks, compared with 21% ± 4% in the controls (Fig-
ure 1F). Tg(KRT5-CreER); Rosa26R-fGFP; Fgfr1+/fx (Fgfr1 condi-
tional heterozygous) mice displayed a phenotype similar to that
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of the cKOs (Figures S2A and S2B). Thus, greater numbers of
both basal and luminal cells are produced by the Fgfr1D/D BCs
than controls, showing that FGFR1 signaling influences the
rate of epithelial cell turnover in the steady-state trachea.
Increased Levels of Basal Cell Proliferation in the Fgfr1
cKO Tracheae
Weassessedproliferation rates usingKI67antibody staining. This
showed that in vivo rates of proliferationwere>3-fold higher in the
Fgfr1D/D BCs than in controls (Figures 2A and 2B). Moreover, the
level ofKi67mRNA inGFP+BCs isolated fromFgfr1 cKO tracheae
Figure 2. Loss of FGFR1 Signaling Results in
Increased Levels of BC Proliferation
(A) Representative confocal sections from control
Tg(KRT5-CreER);Rosa26RfGFP/+andcKOTg(KRT5-
CreER);Rosa26RfGFP/+; Fgfr1D/fx tracheae at 1.5 and
13 weeks after tmx administration. Green, GFP (re-
porter); red, KI67 (proliferating cells); white, KRT5
(BCs); blue, DAPI (nuclei). Arrowheads indicate
KI67+ cells.
(B) Percentage of GFP+ cells that co-express KI67.
(C) Relative expression of Ki67 mRNA in sorted
GFP+ BCs from control and Fgfr1 cKO mice
3 weeks after tmx administration.
(D) Schematic of in vitro experiment.
(E) Low-titer Ad-Cre infection induces sporadic
recombination in control Rosa26RfGFP/+ and cKO
Rosa26RfGFP/+; Fgfr1D/fx BCs. Green, GFP (re-
porter); blue, DAPI (nuclei).
(F) Fgfr1 deletion in vitro results in increased BC
proliferation. Red, KI67 (proliferating cells); blue,
DAPI (nuclei).
(G) Percentage of proliferating (KI67+) cells in vitro.
(H) Schematic for in vitro experiment. Wild-type
(WT) BCs plated at low density (3 3 104 cells/
insert) and exposed to 100 ng/ml FGF2 from day 2.
(I) FGF2-treated and control wild-type BCs at day 4
after plating. Red, E-cadherin (lateral cell mem-
brane); blue, DAPI (nuclei).
(J) Number of DAPI+ cells per colony in control and
FGF2-treated cells.
Error bars denote SEM, Scale bars represent
50 mm in (A), (E), and (F), and 20 mm in (I). See also
Figure S2.
was increased11-fold comparedwithcon-
trols (Figure 2C). Proliferation levels were
intermediate in the Fgfr1 conditional het-
erozygotes (Figure S2C). We confirmed
the increase in BC proliferation in vitro us-
ing a limiting dose of Cre recombinase
adenovirus (Ad-Cre) to induce recom-
bination in small numbers of cells from
Rosa26R-fGFP; Fgfr1D/fx and control
Rosa26R-fGFP tracheae (Figure 2D). The
Fgfr1D/D cells produced larger GFP+ col-
onies than the controls, and these cultures
also contained higher numbers of KI67+
cells (Figures 2E–2G).
We predicted that if deletion of Fgfr1 re-
sults in BC proliferation, activating FGFR1
signaling in vitro would inhibit growth of BC colonies. FGF2 is ex-
pressed in the homeostatic trachea (Figure S1A), is known to
activate FGFR1 preferentially in vitro, and is strongly linked to
FGFR1 activation in multiple in vivo situations (Arai et al., 2015;
Chakkalakal et al., 2012; Garmy-Susini et al., 2004; Hackett
et al., 2011; Hadjab et al., 2013; Kranenburg et al., 2005; Ornitz
et al., 1996). We therefore tested the effects of the addition of
exogenous FGF2 protein on the proliferation of wild-type primary
BCs in culture. We plated wild-type BCs at low density and
added FGF2 on culture day 2 after colonies had become estab-
lished (Figure 2H). As predicted, addition of FGF2 had the
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Figure 3. Loss of FGFR1 Signaling in BCs Leads to an Increase in Phosphorylation of DownstreamEffector Proteins and aDecrease in Levels
of a SPRY2 Isoform
(A) Schematic of in vitro experiment.
(B) Representative western blots from control and Fgfr1 cKO day-5 BCs showing pERK1/2, total ERK1/2, pAKT, total AKT, SPRY2, and histone H3.
(C) Quantification of protein in (B).
(D) Model. A major function of FGFR1 in BCs is to post-translationally modify SPRY2, resulting in a SPRY2 isoform which can negatively regulate the ERK/MAPK
and AKT/PI3K pathways downstream of other RTKs.
(E) Confocal images of control Tg(KRT5-CreER); Rosa26RfGFP/+ and cKO Tg(KRT5-CreER); Rosa26RfGFP/+; Fgfr1D/fx tracheal sections at 1.5 weeks after tmx
administration showingan increase inpERK1/2 levels in theFgfr1 cKOBCs.Green,GFP (reporter); red, pERK1/2 (activeERK1/2); blue,DAPI (nuclei). Scale bar, 25mm.
(legend continued on next page)
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opposite effect to removal of Fgfr1 and significantly reduced col-
ony size (Figures 2I and 2J).
Fgfr1D/D BCs Have Increased Levels of MAPK and AKT
Pathway Activity
To identify the mechanism by which FGFR1 influences BC prolif-
eration, we assessed the levels of activity of well-characterized
downstream intracellular signaling pathways. Given that we
had successfully replicated the proliferation phenotype in pri-
mary cell culture (Figures 2D–2F), we used primary cultures of
Fgfr1D/fx cells with a high dose of Ad-Cre and harvested cells
3 days after infection for western analysis of the whole cell lysate
(Figure 3A). Genotyping of the cultures suggested that many
cells were Fgfr1D/D in these conditions (Figure S3A). These ex-
periments showed that there was a 2.2-fold increase in levels
of phosphorylated ERK1/2 in the Fgfr1D/D cells. In addition, there
was a 3.8-fold increase in total AKT protein and a 1.3-fold in-
crease in the fraction of phosphorylated AKT (Figures 3B and
3C). The change in MAPK pathway activity was confirmed in vivo
by immunostaining for pERK1/2, which showed higher levels in
Fgfr1D/D BCs than controls at 1.5 weeks after tmx administration
(Figure 3E). Thus, the loss of an RTK surprisingly resulted in
increased levels of signaling through the RAS-ERK and PI3K
intracellular pathways, which are typically associated with active
RTK signaling. We therefore analyzed negative regulators of
these signaling cascades. SPRY2 is a well-known transcriptional
target of FGFR signaling and has previously been shown to
be post-translationally modified downstream of FGFR1 activity
in vitro (Lao et al., 2007; Rubin et al., 2005). Two isoforms of
SPRY2 can be separated on polyacrylamide gels. Levels of the
faster-migrating (lower) isoform have been shown in vitro to in-
crease following FGFR1 activation. In addition, this isoform has
a greater ability to bind to GRB2 in vitro and has been proposed
to be the active isoform for inhibition of RAS-ERK signaling (Lao
et al., 2007). Interestingly, in the Fgfr1D/D cells there was a 2.2-
fold decrease in levels of the faster-migrating (lower, active for
ERK/AKT inhibition) SPRY2 isoform and a 1.3-fold increase in
levels of the slower-migrating (upper, unable to inhibit ERK/
AKT) isoform (Figures 3B and 3C). This suggests that a wild-
type function of FGFR1 signaling in the tracheal BCs is to modu-
late SPRY2 activity post-translationally, thus altering the ability
of SPRY2 to inhibit signaling downstream of other RTKs
(Figure 3D).
There is a strong connection between EGFR signaling and
airway BC proliferation (Brechbuhl et al., 2014). We tested the
hypothesis that because the Fgfr1 cKO BCs have more consti-
tutive activity of the ERK/AKT pathways, they would be more
resistant to EGFR inhibition than controls. We grew Fgfr1 cKO
and control BCs in the presence of 0.25 mM of the EGFR inhib-
itor erlotinib (Figure S4A). This resulted in a >5-fold decrease in
proliferation rates in the control cells, versus a 2-fold decrease
in the Fgfr1 cKO cells (Figures S4B–S4D). Moreover, levels of
EGFR protein were unchanged in the Fgfr1 cKO cells (Fig-
ure S4E). The Fgfr1 cKO BCs are thus more resistant to EGFR
inhibition, supporting the hypothesis that the downstream
signaling pathways (ERK/PI3K) are more constitutively active
in these cells.
Stimulating BCs with FGF2 Results in Increased Levels
of the Faster-Migrating SPRY2 Isoform
We tested whether activating FGF signaling is sufficient to
modulate levels of the SPRY2 isoforms in wild-type cells (Fig-
ure 3F). A 10-min or 24-hr FGF2 stimulation resulted in a repro-
ducible small decrease in pERK1/2 compared with control cells,
particularly at the 10-min harvest time (Figures 3G, 3H, and
S5A–S5C). Following FGF2 stimulation we observed no change
in total SPRY2 levels but a 1.6-fold increase in levels of the
faster-migrating SPRY2 isoform (Figures 3G and 3H). These
changes never reached statistical significance. However, the
experiments were performed in primary cells that have multiple
inputs into the ERK pathway in the presence of serum and
the data were reproducible, supporting our hypothesis that
manipulating FGFR1 signaling results in post-translational
changes in SPRY2.
Fgfr1D/D BCs Cannot Produce Ciliated Cells
It has previously been reported that FGFR1 signaling in zebra-
fish and Xenopus embryos can regulate cilia assembly and
length (Hong and Dawid, 2009; Neugebauer et al., 2009). We
therefore examined ciliogenesis in the Fgfr1 cKO tracheae. At
24 weeks after tmx administration, Fgfr1 cKO tracheae had an
excess of GFP+ secretory cells and fewer GFP+ ciliated cells
than the controls (Figures 4A and 4B), suggesting that ciliated
cell production was impaired in the mutant. Indeed, the only
GFP+ ciliated cells that could be detected in the Fgfr1 cKO tra-
chea still retained FGFR1 protein (Figures 4A and 4C), indicating
that they were derived from Fgfr1D/fx cells, which had under-
gone partial recombination to activate the Rosa reporter but
had not deleted the Fgfr1fx allele. Based on scoring the percent-
age of luminal GFP+ cells that retained detectable FGFR1 pro-
tein in these samples, we were able to estimate the rate of
co-recombination of the two floxed alleles as 84% ± 2% (Fig-
ure 4C), in good agreement with our qRT-PCR-based estimate
(Figure 1C).
To assess the stage at which ciliated cell differentiation was
blocked in the Fgfr1 cKO cells, we stained tracheal sections
for the transcription factor FOXJ1, which is expressed during
ciliated cell differentiation and has a role in basal body
anchoring (Blatt et al., 1999; Huang et al., 2003). In the Fgfr1
cKO tracheae the number of GFP+, FOXJ1+ cells was signifi-
cantly decreased, confirming an early block in ciliated cell differ-
entiation (Figures 4B and 4D). These data suggest that in the
Fgfr1 cKO tracheae, luminal cell fate choice is disrupted and
secretory cells are produced at the expense of ciliated cells.
This phenotype is somewhat different to the published role for
FGFR1 in controlling cilia length in multi-ciliated cells in the
(F) Schematic for exposure of wild-type BCs to FGF2.
(G) Representative western blots from day-6 FGF2-stimulated and control BCs showing SPRY2, pERK1/2, total ERK1/2, pAKT, total AKT, and histone H3.
(H) Quantification of protein levels in (G).
Error bars denote SEM. See also Figures S3–S5.
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zebrafish and Xenopus systems (Hong and Dawid, 2009; Neu-
gebauer et al., 2009). This may be a true cross-species differ-
ence or may reflect the limitations of the different experimental
systems used.
Homeostatic production of new ciliated cells occurs at an
extremely slow rate in vivo (Rawlins and Hogan, 2008). To
confirm the ciliated cell differentiation phenotype in the Fgfr1D/D
cells, we grew air-liquid interface (ALI) epithelial cultures from
Rosa26R-fGFP; Fgfr1D/fx and control Rosa26R-fGFP; Fgfr1+/fx
Figure 4. Loss of FGFR1 Signaling Results in
a Block in Ciliated Cell Differentiation
(A) Confocal image of Tg(KRT5-CreER);
Rosa26RfGFP/+; Fgfr1D/fx tracheal section. Green,
GFP (reporter); blue, FGFR1; red, SCGB1A1 (secre-
tory cells); white, acetylated tubulin (ACT, cilia). In the
patch of GFP+ cells marked by the dashed bracket,
FGFR1 is absent and there are no ciliated cells. In the
GFP+ cells within the solid bracket, FGFR1 has not
beendeleted, thereare fewerGFP+cells, andciliated
cell differentiation has occurred.
(B) Percentage of GFP+ cells that co-express
SCGB1A1, ACT, or FOXJ1 in control Tg(KRT5-
CreER);Rosa26RfGFP/+; Fgfr1+/fx and cKO Tg(KRT5-
CreER); Rosa26RfGFP/+; Fgfr1D/fx animals 24 weeks
after tmx administration.
(C) Percentage of GFP+ luminal cells in cKO
Tg(KRT5-CreER); Rosa26RfGFP/+; Fgfr1D/fx trachea
that retain FGFR1 protein 24 weeks after tmx
administration.
(D) Sections from control and Fgfr1 cKO tracheae
at 24 weeks after tmx administration. Green,
GFP (reporter); red, g-tubulin (basal bodies); white,
FOXJ1 (ciliated cells).
(E) Schematic of in vitro experiment.
(F) Day-11 ALI cultures grown from control and
Fgfr1 cKO animals. Green, GFP (reporter); red, ACT
(cilia); blue, DAPI (nuclei).
Error bars denote SEM. Scale bars represent
100 mm in (A) and (F), and 50 mm in (D).
tracheae and deleted the floxed alleles us-
ing Ad-Cre (Figure 4E). All control cultures
had robust differentiation of ciliated cells,
based on acetylated tubulin (ACT) localiza-
tion, but ciliated cells were not observed in
the Fgfr1 cKO cultures (Figure 4F).
In summary, the Fgfr1 cKO BCs have an
increased proliferation rate from 1.5 weeks
after injection. They are also unable to
produce mature ciliated cells, likely due
to a fate-choice defect. We focused on
BC proliferation as the primary phenotype
and, based on our observation that levels
of the fast-migrating SPRY2 isoform
were decreased in the Fgfr1 cKO cells
(Figures 3B and 3C), we hypothesized
that a major role of FGFR1 signaling in
the tracheal BCs is to modulate SPRY2
activity and, moreover, that the function
of SPRY2 in these cells is to inhibit
signaling activity downstream of RTKs
other than FGFR1, for example EGFR, which is necessary for
tracheal BC proliferation (Brechbuhl et al., 2014; Lu et al.,
2013). To test this hypothesis, we deleted Spry2 in BCs of the
adult mouse trachea.
Loss of Spry2 Results in Increased Levels of Tracheal
Basal Cell Proliferation
Spry2 is widely expressed in basal and luminal cells of the ho-
meostatic mouse trachea (Figures 1A and S1). We generated
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Tg(KRT5-CreER); Rosa26R-fGFP; Spry2D/fx (Spry2 cKO) and
control Tg(KRT5-CreER); Rosa26R-fGFP adult mice and admin-
istered tmx to activate GFP and delete Spry2 in a subset of BCs
(Figure 5A). During normal turnover there was an increase in the
proportion of GFP+, Spry2D/D BCs compared with GFP+,
Spry2+/+ controls (Figures 5B and 5C). At the same time the pro-
portion of GFP+, Spry2D/D luminal cells also increased (Figures
5B and 5D). These changes most likely resulted from the
4-fold increase in rates of BC proliferation observed in the
Spry2 cKOs compared with controls (Figures 5E and 5F).
Figure 5. Deletion of Spry2 in BCs Results in
Increased Rates of Proliferation
(A) Schematic of Spry2 conditional knockout
experiment.
(B) Representative confocal sections from control
Tg(KRT5-CreER);Rosa26RfGFP/+andcKOTg(KRT5-
CreER); Rosa26RfGFP/+; Spry2D/fx tracheae. Green,
GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei).
Brackets indicate patches of labeled cells, more
prominent in the Spry2 cKO.
(C) Percentage of the total T1a+ BCs that are also
GFP+.
(D) Percentage of the total T1a luminal cells that
are also GFP+.
(E) Representative confocal sections from control
and cKO tracheae at 1.5 and 13 weeks after tmx
administration. Green, GFP (reporter); red, KI67
(proliferating cells); white, KRT5 (BCs); blue, DAPI
(nuclei). Arrowheads indicate KI67+ cells.
(F) Percentage of GFP+ cells that co-express KI67.
(G) Confocal z projections from sections of control
and Spry2 cKO trachea. Green, GFP (reporter);
red, KRT5 (BCs); white, E-cadherin (lateral cell
membranes); blue, DAPI (nuclei).
Error bars denote SEM. Scale bars represent
50 mm in (B) and (E), and 10 mm in (G). See also
Figure S6.
The proliferation phenotypes were thus
very similar between the Fgfr1 and
Spry2 cKO tracheae, supporting a strong
connection between the two proteins.
However, unlike the Fgfr1 cKO, no ef-
fects on ciliated cell differentiation were
observed in the Spry2 cKO tracheae (Fig-
ures S6A and S6B), suggesting that the
function of FGFR1 in luminal fate choice
is SPRY2 independent. In addition, in
contrast to Fgfr1, no phenotypes were
observed in Spry2 conditional heterozy-
gous tracheae (data not shown).
The Spry2 cKO cells were packedmore
tightly than control cells in the epithelium
(at 13 weeks after tmx administration
there were 16 ± 1.3 cells per 40 mm in
the control tracheal epithelia versus
23.7 ± 1.6 cells per 40 mm in the Spry2
cKOs; p = 0.01; Figure 5B), consistent
with the significantly increased prolifera-
tion rate. However, therewas no evidence
of epithelial stratification, and levels of E-cadherin protein (Fig-
ure 5G) and apical-basal polarity (Figure S6C) appeared normal.
These data suggest that the observed change in cell density may
result from an altered threshold for contact inhibition in the Spry2
cKO cells.
We tested whether we could recapitulate the Spry2 cKO phe-
notypes using Ad-Cre in primary tracheal cell culture (Figure 6A).
Deletion with a high titer of Ad-Cre resulted in loss of all detect-
able SPRY2 protein (Figure 6E) and failure to amplify the Spry2fx
allele from the genomic DNA (Figure S3B), suggesting that we
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Figure 6. Rapidly Proliferating Spry2 Conditional Knockout BCs Have Elevated Levels of RAS-ERK and PI3K Signaling
(A) Schematic of in vitro experiment.
(B)Spry2 cKO (Rosa26RfGFP/+;Spry2D/fx) cells proliferatemore rapidly than controls (Rosa26RfGFP/fGFP) in vitro and aremore densely packed at culture day 5. Note
that not all cKO cells are GFP+, even though SPRY2 protein is undetectable. Green, GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei). Arrowheads indicate
similar regions of the cultures.
(C) Spry2 cKO cells still undergo some contact inhibition in vitro at day 7 after ALI induction. Their proliferation rate slows following induction of ALI and there are
no regions of multi-layering, although KI67+ cells are still visible (arrowhead). Green, GFP (reporter); red, KI67 (proliferating cells); blue, DAPI (nuclei).
(D) Spry2 cKO primary cells continue to proliferate faster in vitro following passage at day 2 after replating. Green, GFP (reporter); red, KI67 (proliferating cells, e.g.
arrowhead); blue, DAPI (nuclei).
(E) Representative western blots from control and Spry2 cKO day-5 BCs showing SPRY2, pAKT, total AKT, pERK1/2, total ERK1/2, SOX2, and histone H3.
(F) Quantification of protein levels. Error bars denote SEM.
(G) Confocal images of control Tg(KRT5-CreER); Rosa26RfGFP/+ and cKO Tg(KRT5-CreER); Rosa26RfGFP/+; SpryD/fx tracheal sections at 1.5 weeks after tmx
administration showing an increase in pERK1/2 levels in the Spry2 cKO BCs. Green, GFP (reporter); red, pERK1/2 (active ERK1/2); blue, DAPI (nuclei).
Scale bars, 25 mm. See also Figure S3.
92 Developmental Cell 37, 85–97, April 4, 2016
achieved complete recombination of the Spry2fx allele. In spite of
this there were large patches of GFP cells in our cultures that
had not recombined the Rosa reporter (Figure 6B). This indicates
that the Spry2fx allele recombines more efficiently than the
Rosa26R-fGFP reporter and supports the conclusion that most
of the GFP+ cells observed in vivo were co-recombinants with
Spry2fx. Therefore, it is likely that scoring GFP+ cells in the
Spry2 cKO tracheae results in a good approximation to the
Spry2D/D phenotype (compare with the Fgfr1 cKO tracheae,
where scoring GFP+ cells results in an underestimate of the
Fgfr1D/D phenotype).
The Spry2D/D cultures had a greater rate of proliferation than
the controls and also reached a higher cell density (Figures 6B
and 6C). Proliferation of the Spry2D/D cells slowed after the cells
reached confluence, but did continue (Figure 6C). Moreover,
confluent cultures could easily be passaged and continued to
show a faster proliferation rate (Figure 6D). Importantly, although
the Spry2D/D cells reached a greater density than controls, we
never observed phenotypes consistent with a complete loss of
contact inhibition, such as multi-layering or cell detachment.
This is again consistent with an altered threshold for, but not
complete loss of, contact inhibition.
Similar to the Fgfr1D/D cells, the Spry2D/D cells had a 3.5-fold
increase in pERK1/2 and a 5.2-fold increase in pAKT levels
compared with the controls (Figures 6E and 6F). These changes
were highly reproducible, although not always statistically signif-
icant. The increase in MAPK pathway activity was confirmed
in vivo by immunostaining for pERK1/2, which showed higher
levels in Spry2D/D BCs than controls at 1.5 weeks after tmx
administration (Figure 6G). We also observed that the Spry2D/D
cells had a 3.3-fold increase in levels of EGFR protein (Figures
6E and 6F). This is consistent with the published function of
the slower-migrating SPRY2 isoform (which is absent in the
Spry2D/D cells, but is unaffected in the Fgfr1D/D cells) in EGFR
trafficking/degradation (Gao et al., 2012; Kim et al., 2007; Walsh
and Lazzara, 2013).
DISCUSSION
The tracheal epithelium is normally quiescent, with a minimal
amount of cell turnover. By combining in vivo genetic analysis
and primary cell culture, we have shown that BC proliferation
is actively repressed under steady-state conditions by an
FGFR1-SPRY2 signaling axis that functions to inhibit signaling
through the ERK and AKT intracellular pathways. This result
argues that airway quiescence does not result simply from the
absence of a proliferative signal or from feedback inhibitory
loops. Rather, we propose a model in which quiescence is
maintained by a balance between signaling mechanisms that
either promote proliferation or repress it. This is an emerging
theme in the stem cell biology of quiescent organs. For
example, a recent publication has found a similar tonic Hedge-
hog signal that inhibits steady-state proliferation in the smaller
mouse airways (Peng et al., 2015), but it is not known whether
this Hedgehog-based mechanism applies in the BC-containing
trachea.
SPRY2 was previously characterized in vitro as a protein
with two isoforms, which can either inhibit ERK/AKT signaling
(faster-migrating SPRY2 isoform) or modulate the subcellular
trafficking/degradation of EGFR protein (slower-migrating iso-
form) (Guy et al., 2009). However, the relative roles of these
SPRY2 isoforms in vivo and how they function downstream of
RTK receptors have not previously been explored. Several lines
of evidence presented here support a model in which the faster-
migrating SPRY2 functions downstream of FGFR1 to control
cell proliferation and tracheal epithelial homeostasis (Figure 7A).
First, following the loss of FGFR1 protein in airway BCs we
observe reduced levels of the faster-migrating (ERK/AKT-inhib-
iting) SPRY2 isoform, as well as increased levels of dpERK
and pAKT, increased rates of proliferation, and increased resis-
tance to EGFR inhibition. By contrast, the slower-migrating
SPRY2 isoform is unaffected (Figure 7B). Second, exposing
wild-type BCs to FGF2 ligand results in increased levels of
Figure 7. Model of the Roles of FGFR1 and
SPRY2 in Airway Basal Cells
(A–C) Model for FGFR1-SPRY2 function in airway
BCs. (A) In wild-type BCs, FGFR1 signaling post-
translationally modifies SPRY2 resulting in an iso-
form of SPRY2 (red), which is able to inhibit ERK/
MAPK and AKT/PI3K signaling downstream of
other RTKs, such as EGFR. This FGFR1-SPRY2
signaling axis limits BC proliferation, resulting in
low levels of steady-state production of new cells.
(B) Following loss of FGFR1 there is amuch smaller
pool of ERK/AKT-inhibiting SPRY2 (red) and,
hence, more active ERK/MAPK and AKT/PI3K
signaling and greater levels of BC proliferation
and production of new basal and luminal cells. In
addition, the Fgfr1D/D cells cannot differentiate as
mature multi-ciliated cells due to a role for FGFR1
signaling in luminal fate choice. (C) Similarly,
following loss of all SPRY2 there is more active
ERK/MAPK and AKT/PI3K signaling and greater
levels of BC proliferation and, hence, production of
new basal and luminal cells. Moreover, a second
isoform of SPRY2 (orange), whichmay regulate the
level of EGFR protein, is also lost. However, FGFR1
is present and ciliated cell differentiation is normal.
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faster-migrating SPRY2, a decrease in dpERK, and inhibition of
BC proliferation. Third, loss of all SPRY2 results in increased
ERK/AKT signaling and BC proliferation (Figure 7C). Taken
together, our data suggest that active FGFR1 signaling in the
steady-state trachea maintains a pool of SPRY2 protein, which
functions to antagonize ERK/AKT signaling and limit cell prolif-
eration downstream of other RTKs, most likely EGFR (Figure 7A).
A relationship between FGFR1 and post-translational modifica-
tion of SPRY2 protein has previously been documented in cell
lines in vitro (Lao et al., 2006, 2007). We now demonstrate its
importance in vivo, clearly illustrating that the context in which
a cell interprets EGFR/RTK signaling can be highly dependent
on the activity of other RTKs present. This has clear implications
for cancer development and the evolution of drug-resistant
tumors.
Another important finding of our work is that FGFR1 and
SPRY2 can also function independently in airway epithelial ho-
meostasis. FGFR1 is required formulti-ciliated cell differentiation
(Figure 4). Moreover, our data suggest that secretory cells are
produced at the expense of ciliated cells by the Fgfr1 cKO
BCs. A role for FGFR1 in ciliated cell differentiation is also consis-
tent with previous reports from other model organisms (Hong
and Dawid, 2009; Neugebauer et al., 2009), but the details of
the cellular requirements remain to be worked out. SPRY2 regu-
lates EGFR protein levels in BCs (Figure 6). Similar observations
have previously been made in vitro or in cancer models, but we
demonstrate this SPRY2-EGFR relationship for the first time in a
homeostatic tissue (Gao et al., 2012; Kim et al., 2007; Walsh and
Lazzara, 2013). SPRY2 thus emerges as a highly flexible switch
that can be modulated by FGFR1 signaling to control different
aspects of RTK signaling. In excess of ten phosphorylation sites
andmultiple binding partners have been documented for SPRY2
in vitro (DaSilva et al., 2006; Edwin et al., 2009; Lao et al., 2007).
These data suggest that SPRY2 is extensively and flexibly
modified in many different cellular settings in vivo and that our
observations may be the tip of the iceberg for the control of
cellular homeostasis by SPRY2.
A key question raised by our model concerns what activates
FGFR1 in vivo. We observed that FGF2 is transcribed in the
tracheal mesenchyme in vivo at steady state, and that recombi-
nant FGF2 inhibits tracheal BC proliferation and modulates
SPRY2 in vitro. These data are consistent with a role for FGF2
in activating FGFR1 signaling in vivo, although we note that other
FGF ligands are expressed in the steady-state airways. Interest-
ingly, in a recent screen of secreted proteins for their effect on
the ability of human airway BCs to form clonal organoids in cul-
ture, addition of FGF2 resulted in smaller tracheospheres with
fewer BCs (Danahay et al., 2015). This is highly consistent with
our in vitro results and suggests that a role for FGF2 signaling
in inhibiting airway BC proliferation is conserved betweenmouse
and humans.
Amplification of the FGFR1 locus, or increased levels of
FGFR1 protein, have been observed in 10%–20% of squamous
lung cancer cell lines, where FGFR1 has been implicated as a
driver mutation and putative therapeutic target (Dutt et al.,
2011; Weiss et al., 2010; Wynes et al., 2014). How do we recon-
cile this increase in FGFR1 expression in airway cancer with our
finding that an FGFR1-SPRY2 signaling module is required to
limit mouse airway BC proliferation at steady state? This will
clearly require future investigation. However, the squamous
cell cancer lines used in these studies were isolated from the
end stage of a cancer development process and have under-
gone many genetic and epigenetic changes. Given the highly
context-dependent and cell-type-specific nature of FGFR1
signaling, and its interaction with SPRY2 and other RTKs as
we have observed, its function may change drastically during
neoplasia development. Nevertheless, we note that if a normal
function of FGFR1 signaling is to inhibit proliferation of wild-
type airway BCs, then it is possible that administration of
FGFR1-specific inhibitors as a cancer therapy may lead to clonal
expansion of other pre-malignant cells.
In conclusion, airway epithelial quiescence requires active
inhibition of proliferation by FGFR1 signaling, which results in
the post-translational modification of SPRY2 and inhibition of
signaling downstream of other RTKs, partly EGFR. We have
thus demonstrated a specific in vivo function for an FGFR1-
SPRY2 signaling axis that was previously documented in vitro.
This illustrates the complexity of RTK signaling networks and
the importance of further investigation in both homeostatic
tissues and developing malignancies.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for a full description of all
materials and methods used.
Mice
Experiments were performed under HomeOffice licenses PPL80/2326 and 70/
812. Fgfr1fx (Xu et al., 2002), Tg(KRT5-CreER) (Rock et al., 2009), Rosa26R-
fGFP (Rawlins et al., 2009), Spry2fx (Shim et al., 2005) were described previ-
ously. Fgfr1D/+ and Spry2D/+ were generated by crossing floxed alleles to
Zp3-Cre (de Vries et al., 2000). All strains weremaintained on a C57Bl/6J back-
ground. Males and females >8 weeks old were used. Wild-type mice were
C57Bl/6J.
Tamoxifen
Animals were injected intraperitoneally with tmx, 0.2 mg/g body weight, four
times every other day.
Tracheal Epithelial Cell Culture
Tracheae were cut into small pieces and incubated in 50% Dispase II (Gibco,
16 U/ml). Epithelial sheets were isolated and dissociated to single cells. Unless
otherwise stated, 5 3 104 cells in 0.5 ml of MTEC/+ medium (You et al., 2002)
were plated on collagen-coated 12-well tissue culture inserts (BD Falcon,
353180). Differentiation was induced in confluent cultures by removal of insert
medium and addition of MTEC serum-free medium to the outer chamber.
Ad-Cre (University of Iowa, Gene Transfer Vector Core) MOI 7 was used
for scattered recombination and MOI 2,500 for complete recombination;
1 3 106 vector plaque-forming units, 100 ng/ml recombinant mouse FGF2,
and 0.25 mM erlotinib (Sigma).
Immunostaining
Cryosections (6 mm) or whole-mount primary cultures were stained with
ACT (mouse, 1:3,000, Sigma, T7451), E-cadherin (rat, 1:3,000, Invitrogen,
13-1900), pERK1/2 (rabbit, 1:200, Cell Signaling Technology, 4695), FGFR1
(rabbit, 1:200, Novus Biologicals, NBP1-20067), FOXJ1 (mouse, 1:200,
eBioscience, clone 2A5, 14-9965-80), GFP (chick, 1:1,000, Abcam,
Ab13970), KRT5 (rabbit, 1:500, Covance, PRB-160P), KI67 (mouse, 1:200,
Becton Dickinson, 550609), SCGB1A1 (goat, 1:400, Santa Cruz Biotech-
nology, sc9772), SPRY2 (rabbit, 1:200, Abcam, Ab50317), and T1a (1:1,000,
DSHB, 8.1.1). Antigen retrieval was in 10 mM boiling sodium citrate for KI67
(pH 8), pERK1/2 (pH 6.5), and FOXJ1 (pH 6). Conjugated secondary
antibodies were Phalloidin-568 and Alexa Fluor (Life Technologies, 1:2,000).
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mRNA In Situ Hybridization
Cryosections (10 mm) were hybridized with DIG-labeled anti-sense mRNA
probes to Fgfr1 (EST: AW495528) or Spry2 (Minowada et al., 1999) (DIG
RNA labeling kit, Roche, 11175025910), and visualized using alkaline phos-
phatase-coupled anti-DIG (1:2,000, Roche, 12930023) and BCIP/NBT (Roche,
1383213).
Microscopy and Image Scoring
Slides were imaged on a Zeiss AxioImager compound microscope or a Leica
Sp8/Sp5 confocal microscope as stated. Cells were scored manually in Fiji
(ImageJ), or using the Gurdon Institute Imaging Facility’s plugin ObjectScan.
For cryosections, every epithelial cell along the entire proximal to distal length
of a longitudinal section from the center of the trachea was scored. BCs were
T1a+ or KRT5+ with the apical surface not reaching the lumen. For cultured
cells, at least three random fields of view per insert were scored.
RT-PCR
Samples were enriched for epithelium or mesenchyme using Dispase diges-
tion and manual peeling. Total RNA was extracted using TRIzol reagent.
qRT-PCR
Primary tracheal epithelial cells were isolated and sorted using a fluorescence-
activated cell sorting MoFlo flow cytometer. Wild-type cells were gated as
basal EpCAM, GSIb4 lectin; secretory EpCAM, SSEA1; and ciliated EpCAM,
CD24. GFP+ BCs from control and Fgfr1 cKO tracheae were sorted as GFP,
GSIb4 lectin. Total RNA was extracted using a Qiagen RNEasy Mini Kit, and
Taqman gene expression assays (Life Technologies) were used.
Immunoblots
Cells were collected in Cell Extraction Buffer (Invitrogen, FNN0011) with
protease inhibitor (Roche, 04693116001) and PMSF (Sigma, P7626). Proteins
were separated on 10% or 12% SDS-PAGE gels before transfer to Millipore
Immobilon-P PVDF Membrane (Merck Millipore, IPVH00010). Membranes
were probed with pAKT(S473) (Cell Signaling, 3787, 1:3,000), pan-AKT (Cell
Signaling, 4691, 1:1,000), dpERK1/2 (Cell Signaling, 4370, 1:300), ERK1/2
(Cell Signaling, 4695, 1:300), SPRY2 (Abcam, Ab50317, 1:300), SOX2 (Abcam,
Ab97959, 1:3,000), Histone H3 (Abcam, Ab39655, 1:10,000), and EGFR
(Millipore, 04-290, 1:300). Detection was performed with horseradish peroxi-
dase-conjugated secondaries (Abcam, ab97051, ab97023, 1:10,000) and
enhanced chemiluminescence (Thermo Scientific, PI-32109). Quantitation is
based on analysis of protein from three biological replicates separated on
the same polyacrylamide gel. Band intensity was analyzed in Fiji normalized
to loading control.
Statistics
Statistics were calculated using Student’s two-tailed t test with unequal
variance.
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